Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare?

Urology

Volumn 75, Issue 3, 2010, Pages 642-647

  Oh, William K ^a   Landrum, Mary Beth ^b   Lamont, Elizabeth B ^b,c   McNeil, Barbara J ^b   Keating, Nancy L ^b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NARCOTIC AGENT; NILUTAMIDE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; CANCER PAIN; CANCER PATIENT; CANCER PREVENTION; CLINICAL ASSESSMENT; CLINICAL FEATURE; FRACTURE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SPINAL CORD COMPRESSION; TESTOSTERONE BLOOD LEVEL; TREATMENT INDICATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 77649179119     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.08.008     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
3. Furr B.J. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res 32 suppl 1 (1989) 86-92
4. Bubley G.J. Is the flare phenomenon clinically significant?. Urology 58 (2001) 5-9
5. Mahler C. Is disease flare a problem?. Cancer 72 (1993) 3799-3802
6. Thompson I.M. Flare associated with LHRH-agonist therapy. Rev Urol 3 suppl 3 (2001) S10-S14
7. Kuhn J.M., Billebaud T., Navratil H., et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321 (1989) 413-418
8. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
9. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
10. Townsend M.F., Sanders W.H., Northway R.O., et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79 (1997) 545-550
11. Thompson I.M., Zeidman E.J., and Rodriguez F.R. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144 (1990) 1479-1480
12. Kahan A., Delrieu F., Amor B., et al. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet 1 (1984) 971-972
13. Reid P., Kantoff P., and Oh W. Antiandrogens in prostate cancer. Invest New Drugs 17 (1999) 271-284
14. Labrie F., Dupont A., Belanger A., et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138 (1987) 804-806
15. National Comprehensive Cancer Network (NCCN). Prostate Cancer Practice Guidelines in Oncology, v.1.2008 (2008), NCCN, Fort Washington, PA
16. Charlson M., Szatrowski T.P., Peterson J., et al. Validation of a combined comorbidity index. J Clin Epidemiol 47 (1994) 1245-1251
17. Klabunde C.N., Potosky A.L., Legler J.M., et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 53 (2000) 1258-1267
18. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
19. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostatic Cancer (1999), Agency for Health Care Policy and Research, US Department of Health and Human Services, Rockville, MD AHCPR Publication No. 99-E0012